Phase 1 PK study to evaluate the PK of CIN-107 in subjects with hepatic impairment

Trial Identifier: CIN-107-115
Sponsor: AstraZeneca
NCTID:: NCT05961397
Start Date: August 2021
Primary Completion Date: April 2022
Study Completion Date: April 2022
Condition: Hypertension

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States, California Rialto, California, United States, 92377
United States, Florida Miami, Florida, United States, 33147
United States, Florida Orlando, Florida, United States, 32809
United States, Tennessee Knoxville, Tennessee, United States, 37920
United States, Texas San Antonio, Texas, United States, 78215